To our knowledge, there have been no previous large-scale retrospective studies investigating the efficacy and prognostic predictors of ICI plus chemotherapy versus platinum-based treatment in patients with NSCLC and a PD-L1 TPS of 1% to 49%. This evidence concerns the gene CD274 and non-small cell lung carcinoma.